| Literature DB >> 31905036 |
Elena Campione1, Caterina Lanna1, Laura Diluvio1, Maria Vittoria Cannizzaro1, Sandro Grelli2, Marco Galluzzo1, Marina Talamonti1, Margherita Annicchiarico-Petruzzelli3, Mara Mancini3, Gerry Melino2,3, Eleonora Candi2, Gianfranco Schiavone4, Ying Wang5, Yufang Shi6,7, Luca Bianchi1.
Abstract
While the epidermis is the frontline defense against infections and indeed, it is a peripheral lymphoid organ, the same immunological mechanisms may initiate and sustain pathological conditions. Indeed, a deregulated action against exogenous pathogens could activate a T cell response in atopic dermatitis, hidradenitis suppurativa and vitiligo. Atopic dermatitis (AD) is a chronic inflammatory skin condition with a complex pathophysiology. Although T helper 2 immunity dysregulation is thought to be the main cause of AD etiopathogenesis, the triggering mechanism is not well understood, and the treatment is often difficult. As the AD, hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a dramatic impact on the quality of life of the affected patients. The exact pathophysiology of HS is still unclear, but many evidences report a follicular obstruction and subsequent inflammation with TNF-α, interleukin (IL)-1β, IL-10, and IL-17 involvement. Vitiligo is an autoimmune epidermal disorder which consists of melanocytes destruction and skin depigmentation. Melanocytes destruction is mainly due to their increased oxidative-stress sensitivity with a consequent activation of innate first and adaptative immunity (CD8+ T cells) later. The understanding of the triggering mechanisms of AD, HS and Vitiligo is pivotal to outline novel therapies aimed at regaining the physiological immune homeostasis of healthy skin. The aim of this review is to provide new insight on the pathogenesis of these skin diseases and to highlight on the new therapeutic approaches adopted in the treatment of AD, HS and Vitiligo.Entities:
Keywords: Atopic dermatitis; hidradenitis suppurativa; vitiligo
Mesh:
Substances:
Year: 2020 PMID: 31905036 PMCID: PMC7028161 DOI: 10.1080/15384101.2019.1707455
Source DB: PubMed Journal: Cell Cycle ISSN: 1551-4005 Impact factor: 4.534